Company Encyclopedia
View More
name
Immunome
IMNM.US
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc.
1.946 T
IMNM.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking204/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-93.04%E
    • Profit Margin-2301.30%E
    • Gross Margin0.00%E
  • Growth ScoreC
    • Revenue YoY-4.44%D
    • Net Profit YoY27.05%B
    • Total Assets YoY16.54%A
    • Net Assets YoY22.81%A
  • Cash ScoreD
    • Cash Flow Margin-4.35%D
    • OCF YoY-4.44%D
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreA
    • Gearing Ratio11.84%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Immunome (NASDAQ:IMNM) Sets New 12-Month High - Here's Why

    Immunome, Inc. (NASDAQ:IMNM) reached a new 52-week high, trading at $19.1150. Analysts have mixed ratings: Weiss Ratings issued a 'sell' rating, while Goldman Sachs and others have 'buy' ratings with price targets up to $26. The stock has a market cap of $1.71 billion and a P/E ratio of -6.32. Institutional investors have increased their holdings, with 44.58% of the stock owned by them. Despite a Moderate Buy consensus, some analysts suggest better investment options.

    Market Beat·
    US
    IMNM
    +3.72%
    Market Beat·
    US
    IMNM
    +3.72%

    Immunome to Present at Upcoming Investor Conferences

    Immunome Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference and the 8th Annual Evercore Healthcare Conference on December 3, 2025. Live audio webcasts of the presentations will be available on the company's Investor Relations website, with replays accessible for 30 days post-event.

    Reuters·
    US
    IMNM
    +3.72%
    Reuters·
    US
    IMNM
    +3.72%

    Lake Street Sticks to Their Buy Rating for Immunome (IMNM)

    Lake Street's Chad Messer maintains a Buy rating for Immunome (IMNM) with a $22 price target. Messer, who covers the Healthcare sector, has an average return of -0.7% and a 37.91% success rate. Immunome also received a Buy rating from Stephens's Sudan Loganathan, while TR reiterated a Hold rating on November 12.

    Tip Ranks·
    US
    IMNM
    +3.72%
    Tip Ranks·
    US
    IMNM
    +3.72%

    Immunome’s Strategic Clinical Advancements and Financial Alignment Justify Buy Rating

    TD Cowen analyst Tyler Van Buren has maintained a Buy rating on Immunome (IMNM) stock, citing the company's recent financial performance and ongoing clinical trials. Following the third-quarter earnings report, expense estimates were adjusted to align with costs for key trials, including Phase III varegacestat and Phase I IM-1021. This strategic alignment suggests a focused approach to advancing clinical programs, enhancing the company's growth prospects. Piper Sandler also issued a Buy rating with a $21.00 price target on the same day.

    Tip Ranks·
    US
    IMNM
    +3.72%
    Tip Ranks·
    US
    IMNM
    +3.72%

    Immunome, Inc. Reports Q3 2025 Financial Results

    Immunome, Inc. (IMNM) reported its Q3 2025 financial results, showing a significant increase in cash and cash equivalents to $272.6 million from $143.4 million in 2024. The company incurred a net loss of $57.5 million due to higher R&D expenses. Despite no collaboration revenue, Immunome raised $161.7 million through a public offering and $44.9 million via an ‘at the market’ sales agreement. Management expects current resources to support operations for at least 12 months while planning to seek additional capital for long-term goals.

    Tip Ranks·
    US
    IMNM
    +3.72%
    Tip Ranks·
    US
    IMNM
    +3.72%
    © 2025 Longbridge｜Disclaimer